Foscarnet for chronic hepatitis B
暂无分享,去创建一个
[1] O. Weiland,et al. Treatment of chronic replicative hepatitis B virus infection with short-term continuous infusion of foscarnet , 1994, Infection.
[2] A. Vegnente,et al. Chronicity rate of hepatitis B virus infection in the families of 60 hepatitis B surface antigen positive chronic carrier children: Role of horizontal transmission , 1992, European Journal of Pediatrics.
[3] K. Meyer zum Büschenfelde,et al. Inhibition of hepatitis B virus specific DNA polymerase by intercalating agents , 1980, Medical Microbiology and Immunology.
[4] B. McMahon,et al. Chronic hepatitis B , 2001, Hepatology.
[5] Christian Gluud,et al. Reported Methodologic Quality and Discrepancies between Large and Small Randomized Trials in Meta-Analyses , 2001, Annals of Internal Medicine.
[6] Douglas G Altman,et al. Systematic reviews in health care: Assessing the quality of controlled clinical trials. , 2001, BMJ.
[7] V. Thakur,et al. Transfusion‐Associated Hepatitis in a Tertiary Referral Hospital in India , 1999, Vox sanguinis.
[8] A. M. Ferreira,et al. Prevalência de marcadores sorológicos do vírus da hepatite B em trabalhadores do serviço hospitalar , 1999 .
[9] J. V. Fernandes,et al. [Prevalence of serologic markers of hepatitis B virus in hospital personnel]. , 1999, Revista de saude publica.
[10] L. Simonsen,et al. Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: model-based regional estimates. , 1999, Bulletin of the World Health Organization.
[11] B. Hirschel,et al. Prevalence and incidence rate of HIV, hepatitis B and C among drug users on methadone maintenance treatment in Geneva between 1988 and 1995 , 1998, AIDS.
[12] D. Cook,et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? , 1998, The Lancet.
[13] K. Chayama,et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. , 1998, Journal of hepatology.
[14] W. M. Lee,et al. Hepatitis B virus infection. , 1997, The New England journal of medicine.
[15] G. Smith,et al. Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.
[16] Á. Atallah,et al. Optimal search strategy for clinical trials in the Latin American and Caribbean Health Science Literature Database (LILACS). , 1997, Sao Paulo medical journal = Revista paulista de medicina.
[17] A R Jadad,et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.
[18] R. J. Hayes,et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. , 1995, JAMA.
[19] J. Hoofnagle,et al. Classification of chronic hepatitis: Diagnosis, grading and staging , 1994, Hepatology.
[20] H. Thomas,et al. Genetic variation in hepatitis B virus. , 1992, Gastroenterology.
[21] S. Della Bella,et al. Epidemiology of viral hepatitis in dialysis centers: a national survey. , 1992, Nephron.
[22] H. Margolis,et al. Hepatitis B: Evolving Epidemiology and Implications for Control , 1991, Seminars in liver disease.
[23] D. Heymann,et al. Transmission of HIV, hepatitis B virus, and other bloodborne pathogens in health care settings: a review of risk factors and guidelines for prevention. World Health Organization. , 1991, Bulletin of the World Health Organization.
[24] Kingsley,et al. Sexual transmission efficiency of hepatitis B virus and human immunodeficiency virus among homosexual men. , 1990, Critical care nurse.
[25] H. Daniels,et al. Foscarnet therapy in chronic hepatitis B virus e antigen carriers , 1989, Journal of medical virology.
[26] J. Hoofnagle,et al. Chronic type B hepatitis and the “healthy” Hbsag carrier state , 1987, Hepatology.
[27] M. Colombo,et al. A multicenter, prospective study of posttransfusion hepatitis in milan , 1987, Hepatology.
[28] M. Alter,et al. Hepatitis B virus transmission between heterosexuals. , 1986, JAMA.
[29] N. Laird,et al. Meta-analysis in clinical trials. , 1986, Controlled clinical trials.
[30] T R Bender,et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. , 1985, The Journal of infectious diseases.
[31] B. Öberg. Antiviral effects of phosphonoformate (PFA, foscarnet sodium). , 1982 .
[32] Neil Kaplowitz,et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis , 1981, Hepatology.
[33] H. Balfour,et al. Transmission of hepatitis B virus in clinical laboratory areas. , 1979, Journal of Infectious Diseases.
[34] C E Stevens,et al. The e antigen and vertical transmission of hepatitis B surface antigen. , 1977, American journal of epidemiology.
[35] M. Hatch,et al. Epidemic viral hepatitis, type B, in hospital personnel. , 1974, The American journal of medicine.